Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun;20(2):362-371.
doi: 10.1111/vco.12799. Epub 2022 Jan 17.

The role of toceranib phosphate in dogs with non-mast cell neoplasia: A systematic review

Petros Frezoulis  1 , Aaron Harper  2
Affiliations

The role of toceranib phosphate in dogs with non-mast cell neoplasia: A systematic review

Petros Frezoulis et al. Vet Comp Oncol. 2022 Jun.

Abstract

The use of tyrosine kinase inhibitors (TKI) has gained significant importance in veterinary cancer patients over the last decade. Toceranib phosphate has been licensed for the treatment of dogs with mast cell tumours. Its molecular similarity to sunitinib, a TKI used in human medicine, has led many veterinary oncologists to use this agent for multiple neoplastic diseases. The aim of the current study was to perform a systematic review of the evidence for the use of toceranib in dogs with non-mast cell neoplasia. Two electronic databases were searched. Publications were included if toceranib was used as a treatment option in canine patients. Studies and case reports were excluded if toceranib was used as part of a multi-modal treatment plan and response or outcome data related to toceranib therapy were not described. A total of 28 studies were included from 122 references. The most common types of neoplasias identified were neuroendocrine tumours, anal gland sac adenocarcinoma, and osteosarcoma. Multiple other neoplasias had one or two studies identified to describe the use of toceranib. Results of the study support that toceranib phosphate may have efficacy against certain types of neoplasia under certain conditions, such as neuroendocrine tumours, gastrointestinal stromal tumours and anal sac adenocarcinomas, while it is probably not effective for the management of metastatic osteosarcoma based on the findings of the review.

Keywords: canine; oncology; precision medicine; veterinary.

PubMed Disclaimer

References

REFERENCES

    1. Lemmon MA, Schlessinger J. Cell signaling by receptor-tyrosine kinases. Cell. 2010;141(7):1117-1134.
    1. London CA. Small molecule inhibitors in veterinary oncology practice. Vet Clin North Am - Small Anim Pract. 2014;44(5):893-908.
    1. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell. 2011;144(5):646-674.
    1. London CA, Malpas PB, Wood-follis SL, et al. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin Cancer Res. 2009;15(11):3856-3866.
    1. Hahn K, Oglivie G, Rusk T, et al. Masitinib is safe and effective for the treatment of canine mast cell tumors. J Vet Intern Med. 2008;22:1301-1309.

Publication types

LinkOut - more resources